EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
NCT02533115
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Secondary AML
Interventions
DRUG:
CPX-351
Sponsor
Jazz Pharmaceuticals